Study of Helicobacter pylori eradication therapy using vonoprazan

Study of Helicobacter pylori eradication therapy using vonoprazan - Study of Helicobacter pylori eradication therapy using vonoprazan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019158

Enrollment

2000

Registered

2015-10-01

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter infection

Interventions

Vonoprazan 20mg bid Amoxicillin 750mg bid Clarithromycin 400mg bid or metronidazole 250mg bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Helicobacter infection

Exclusion criteria

Exclusion criteria: Patients who received eradication therapy more than once Allergy for the study drugs Patients in need treatment with PPI Postoperative stomach Routine use of anticoagulant or low-dose aspirin, NSAIDS, steroids Severe major organ dysfunction

Design outcomes

Primary

Measure	Time frame
Eradication rate of Helicobacter pylori after treatment	—

Secondary

Measure	Time frame
Rate of adverse events	—

Countries

Japan

Contacts

Public ContactHisashi Ishikawa

Tsuyama Chuo Hospital Department of Gastroenterology

hisashi.ishikawaq@gmail.com0868-26-2188

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026